NAPP-19 may be particularly useful as anovel biomarker of synaptic health, cognitive decline, and AD pathology.While peptides from VGF are generally decreased in AD-DEM, peptidesfrom CHGA showed an opposite pattern with some peptides showing increasesin AD-DEM and Frail individuals compared to Controls in brain. This evidence concerns the gene VGF and Alzheimer disease.